You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Colorcon
Baxter
McKesson
Boehringer Ingelheim
Merck
Medtronic

Last Updated: February 23, 2020

DrugPatentWatch Database Preview

Drugs in Development Information for C1-INH


Email this page to a colleague

See Plans and Pricing

« Back to Dashboard

What is the development status for investigational drug C1-INH?

C1-INH is an investigational drug.

There have been 5 clinical trials for C1-INH. The most recent clinical trial was a Phase 1 trial, which was initiated on November 16th 2016.

The most common disease conditions in clinical trials are Ischemia, Wounds and Injuries, and Reperfusion Injury. The leading clinical trial sponsors are Universitaire Ziekenhuizen Leuven, CSL Behring, and T. van der Poll.

There are fourteen US patents protecting this investigational drug and eighty-eight international patents.

Recent Clinical Trials for C1-INH
TitleSponsorPhase
Efficacy and Safety of Human Plasma-derived C1-esterase Inhibitor as add-on to Standard of Care for the Treatment of Refractory Antibody Mediated Rejection (AMR) in Adult Renal Transplant RecipientsCSL BehringPhase 3
C1-inhibitor in Allergic ASThma PatientsSanquinPhase 4
C1-inhibitor in Allergic ASThma PatientsZonMw: The Netherlands Organisation for Health Research and DevelopmentPhase 4

See all C1-INH clinical trials

Clinical Trial Summary for C1-INH

Top disease conditions for C1-INH
Top clinical trial sponsors for C1-INH

See all C1-INH clinical trials

US Patents for C1-INH

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
C1-INH   Start Trial Compositions and methods useful for the treatment of neuromyelitis optica spectrum disorders SHIRE VIROPHARMA INCORPORATED (Lexington, MA)   Start Trial
C1-INH   Start Trial Protein biomarkers for immune assessment and prediction of transplant rejection THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (Oakland, CA)   Start Trial
C1-INH   Start Trial Combination therapy using immunoglobulin and C1-Inhibitor CSL BEHRING GMBH (Marburg, DE) THE GOVERNMENT OF THE UNITED STATES OF AMERICA (Rockville, MD)   Start Trial
C1-INH   Start Trial Compositions and methods for treating neonatal biliary atresia Children's Hospital Medical Center (Cincinnati, OH)   Start Trial
C1-INH   Start Trial Process for the purification of C1-inhibitor The United States of America as represented by the Secretary of the (Washington, DC)   Start Trial
C1-INH   Start Trial Process for preparing a C1-esterase inhibitor concentrate (C1-INH), and concentrate obtained, for therapeutic use Association pour l'Essor de la Transfusion Sanguine dans (Lille, FR)   Start Trial
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for C1-INH

Drugname Country Document Number Estimated Expiration Related US Patent
C1-INH Australia 2015243424 2034-04-09   Start Trial
C1-INH Canada 2944990 2034-04-09   Start Trial
C1-INH European Patent Office 3129781 2034-04-09   Start Trial
C1-INH Japan 2017513009 2034-04-09   Start Trial
C1-INH South Korea 20160142390 2034-04-09   Start Trial
C1-INH World Intellectual Property Organization (WIPO) 2015157546 2034-04-09   Start Trial
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Moodys
Boehringer Ingelheim
Medtronic
Johnson and Johnson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.